Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas.

Author information

Affiliations

  • 1. Department of Biomedicina dell'Età Evolutiva, University of Bari, Italy.
      Authors
    • Iolascon A 1
    (1 author)

ORCIDs linked to this article

British Journal of Cancer, 01 Mar 2000, 82(6):1171-1176
https://doi.org/10.1054/bjoc.1999.1058 PMID: 10735501 PMCID: PMC2363349

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Transforming growth factor beta (TGF-beta) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-beta action is a characteristic of many malignancies and has been attributed to alterations of TGF-beta receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-beta response in neuroblastoma, the expression of TGF-beta1 and TGF-beta type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-beta1 and TGF-beta type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-beta type III receptor gene expression, which is required for an efficacious TGF-beta binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-beta response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-beta type III receptor gene expression, to avoid TGF-beta inhibitory activity.

Free full text 

Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2000 Mar; 82(6): 1171–1176.
Published online 2000 Feb 21. https://doi.org/10.1054/bjoc.1999.1058
PMCID: PMC2363349
PMID: 10735501

Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas

A Iolascon,1 L Giordani,1 A Borriello,2 R Carbone,1 A Izzo,1 G P Tonini,4 C Gambini,3 and F Della Ragione2
Author information Article notes Copyright and License information Disclaimer
Abstract

Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. © 2000 Cancer Research Campaign

Keywords: TGF-β1, TGF-βRI, TGF-βRII, TGF-βRIII, neuroblastoma
Full Text
The Full Text of this article is available as a PDF (127K).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer. 1999 Feb 1;85(3):658–668. [Abstract] [Google Scholar]
  • Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. [Abstract] [Google Scholar]
  • Chen C, Wang XF, Sun L. Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem. 1997 May 9;272(19):12862–12867. [Abstract] [Google Scholar]
  • Coffey RJ, Jr, Kost LJ, Lyons RM, Moses HL, LaRusso NF. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J Clin Invest. 1987 Sep;80(3):750–757. [Europe PMC free article] [Abstract] [Google Scholar]
  • Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res. 1995 Jun 1;55(11):2380–2386. [Abstract] [Google Scholar]
  • Filmus J, Kerbel RS. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol. 1993 Jan;5(1):123–129. [Abstract] [Google Scholar]
  • Filmus J, Zhao J, Buick RN. Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones. Oncogene. 1992 Mar;7(3):521–526. [Abstract] [Google Scholar]
  • Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog. 1993;4(5):493–540. [Abstract] [Google Scholar]
  • Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997 Dec 4;390(6659):465–471. [Abstract] [Google Scholar]
  • Hougaard S, Nørgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Skovgaard Poulsen H. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer. 1999 Mar;79(7-8):1005–1011. [Europe PMC free article] [Abstract] [Google Scholar]
  • Iolascon A, Giordani L, Moretti A, Tonini GP, Lo Cunsolo C, Mastropietro S, Borriello A, Ragione FD. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr Res. 1998 Jan;43(1):139–144. [Abstract] [Google Scholar]
  • Iolascon A, Giordani L, Moretti A, Basso G, Borriello A, Della Ragione F. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. Hepatology. 1998 Apr;27(4):989–995. [Abstract] [Google Scholar]
  • Iolascon A, Lo Cunsolo C, Giordani L, Cusano R, Mazzocco K, Boumgartner M, Ghisellini P, Faienza MF, Boni L, De Bernardi B, et al. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. Cancer Lett. 1998 Aug 14;130(1-2):83–92. [Abstract] [Google Scholar]
  • Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. Expression and structure of the human NGF receptor. Cell. 1986 Nov 21;47(4):545–554. [Abstract] [Google Scholar]
  • Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002–6006. [Europe PMC free article] [Abstract] [Google Scholar]
  • Kiefer MC, Stephans JC, Crawford K, Okino K, Barr PJ. Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6985–6989. [Europe PMC free article] [Abstract] [Google Scholar]
  • Kimchi A, Wang XF, Weinberg RA, Cheifetz S, Massagué J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science. 1988 Apr 8;240(4849):196–199. [Abstract] [Google Scholar]
  • López-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell. 1991 Nov 15;67(4):785–795. [Abstract] [Google Scholar]
  • López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 1993 Jul 2;73(7):1435–1444. [Abstract] [Google Scholar]
  • Lu SL, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun. 1995 Nov 13;216(2):452–457. [Abstract] [Google Scholar]
  • MacDonald RG, Pfeffer SR, Coussens L, Tepper MA, Brocklebank CM, Mole JE, Anderson JK, Chen E, Czech MP, Ullrich A. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science. 1988 Mar 4;239(4844):1134–1137. [Abstract] [Google Scholar]
  • Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995 Jun 2;268(5215):1336–1338. [Abstract] [Google Scholar]
  • Matoba H, Sugano S, Yamaguchi N, Miyachi Y. Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma. Horm Metab Res. 1998 Oct;30(10):624–628. [Abstract] [Google Scholar]
  • Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature. 1987 Sep 24;329(6137):301–307. [Abstract] [Google Scholar]
  • Polyak K. Negative regulation of cell growth by TGF beta. Biochim Biophys Acta. 1996 Mar 18;1242(3):185–199. [Abstract] [Google Scholar]
  • Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM. Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature. 1987 Feb 12;325(6105):593–597. [Abstract] [Google Scholar]
  • Royuela M, De Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors. 1998;16(2):101–110. [Abstract] [Google Scholar]
  • Saunders S, Jalkanen M, O'Farrell S, Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol. 1989 Apr;108(4):1547–1556. [Europe PMC free article] [Abstract] [Google Scholar]
  • Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994 Oct 21;269(42):26449–26455. [Abstract] [Google Scholar]
  • Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA. Expression cloning and characterization of the TGF-beta type III receptor. Cell. 1991 Nov 15;67(4):797–805. [Abstract] [Google Scholar]
  • Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem. 1996 Jul 19;271(29):17366–17371. [Abstract] [Google Scholar]
  • White RL. Tumor suppressing pathways. Cell. 1998 Mar 6;92(5):591–592. [Abstract] [Google Scholar]
Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Full text links 

Read article at publisher's site: https://doi.org/10.1054/bjoc.1999.1058

Read article for free, from open access legal sources, via Unpaywall: https://www.nature.com/articles/6691058.pdfUnpaywall

Citations & impact 

Impact metrics

22
Citations
Jump to Citations

Citations of article over time

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1054/bjoc.1999.1058

Supporting
Mentioning
Contrasting
1
16
0

Article citations

Go to all (22) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.